Insmed (NASDAQ:INSM) Price Target Increased to $40.00 by Analysts at Barclays

Insmed (NASDAQ:INSM - Free Report) had its target price boosted by Barclays from $37.00 to $40.00 in a report released on Thursday morning, Benzinga reports. Barclays currently has an overweight rating on the biopharmaceutical company's stock.

A number of other brokerages have also recently commented on INSM. UBS Group assumed coverage on shares of Insmed in a research report on Tuesday, February 27th. They issued a buy rating and a $46.00 target price on the stock. Wolfe Research began coverage on shares of Insmed in a research report on Thursday, February 15th. They issued an outperform rating and a $42.00 price objective on the stock. Wells Fargo & Company restated an overweight rating and issued a $55.00 price objective on shares of Insmed in a research report on Monday, April 1st. Guggenheim boosted their price objective on shares of Insmed from $52.00 to $54.00 and gave the company a buy rating in a research report on Tuesday, February 27th. Finally, StockNews.com upgraded shares of Insmed from a sell rating to a hold rating in a research report on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat, Insmed presently has an average rating of Moderate Buy and a consensus target price of $44.64.

Insmed Trading Up 0.6 %

Shares of Insmed stock traded up $0.17 on Thursday, hitting $28.56. 1,000,761 shares of the company traded hands, compared to its average volume of 1,668,311. The firm's 50-day simple moving average is $27.69 and its 200 day simple moving average is $27.00. The company has a market cap of $4.24 billion, a P/E ratio of -5.35 and a beta of 0.92. Insmed has a 12-month low of $16.46 and a 12-month high of $32.00.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.15). The company had revenue of $83.70 million for the quarter, compared to the consensus estimate of $82.15 million. The firm's revenue for the quarter was up 41.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.20) EPS. Analysts predict that Insmed will post -4.65 earnings per share for the current year.

Insider Activity

In other news, insider Martina M.D. Flammer sold 4,667 shares of Insmed stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $28.63, for a total transaction of $133,616.21. Following the sale, the insider now owns 106,898 shares of the company's stock, valued at approximately $3,060,489.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, COO Roger Adsett sold 5,251 shares of Insmed stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $28.63, for a total transaction of $150,336.13. Following the sale, the chief operating officer now owns 148,559 shares of the company's stock, valued at approximately $4,253,244.17. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Martina M.D. Flammer sold 4,667 shares of the business's stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $28.63, for a total transaction of $133,616.21. Following the sale, the insider now directly owns 106,898 shares in the company, valued at approximately $3,060,489.74. The disclosure for this sale can be found here. Insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On Insmed

A number of hedge funds and other institutional investors have recently bought and sold shares of INSM. International Assets Investment Management LLC purchased a new stake in Insmed in the fourth quarter worth about $25,000. Almanack Investment Partners LLC. purchased a new stake in Insmed in the third quarter worth about $25,000. State of Wyoming purchased a new stake in Insmed in the fourth quarter worth about $31,000. Quantbot Technologies LP grew its holdings in Insmed by 2,170.4% in the second quarter. Quantbot Technologies LP now owns 2,452 shares of the biopharmaceutical company's stock worth $48,000 after purchasing an additional 2,344 shares during the period. Finally, RVW Wealth LLC purchased a new stake in Insmed in the third quarter worth about $53,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.